Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.
Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC
Adagrasib (MRTX849) yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C-mutant advanced non-small cell lung cancer,...
Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33502820/
Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantification of nucleic acid sequences. We used absolute quantification of mutated v-Ki-ras2 Kirsten rat sarcoma viral...
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33722854/
doi: 10.1158/1535-7163.MCT-20-0462. Online ahead of print. 1 Research, Mirati Therapeutics (United States). 2 cancer center, New York University School of Medicine. 3 Research - Biology, Mirati Therapeutics (United States). 4...
KRAS G12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33718018/
1 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Pulmonary Medicine, Berlin, Germany. 2 Helios...
The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947398/
Peter Radeczky, 1, 2 Zsolt Megyesfalvi, 1, 2, 3 Viktoria Laszlo, 2, 3 Janos Fillinger, 1, 2 Judit Moldvay, 2, 4 Erzsebet Raso, 5 Erzsebet Schlegl, 2 Tamas Barbai, 5...